INLX
Intellinetics, Inc.
Software - Application
Market Cap$32M
5Y Perf.+69.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
INLX vs OTLK
Revenue, margins, valuation, and 5-year total return — side by side.
OTLK
Outlook Therapeutics, Inc.
Biotechnology
Market Cap$14M
5Y Perf.-98.9%
INLX vs OTLK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | INLX | OTLK |
|---|---|---|
| Industry | Software - Application | Biotechnology |
| Market Cap | $32M | $14M |
| Revenue (TTM) | $17M | $206K |
| Net Income (TTM) | $-2M | $-103M |
| Gross Margin | 64.6% | -5.9% |
| Operating Margin | -9.6% | -286.8% |
| Total Debt | $4M | $247.70B |
| Cash & Equiv. | $2M | $8.08T |
INLX vs OTLK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
INLX
OTLK
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Intellinetics, Inc. (INLX) | 100 | 169.0 | +69.0% |
| Outlook Therapeutic… (OTLK) | 100 | 1.1 | -98.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INLX vs OTLK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: INLX and OTLK are tied at the top with 2 categories each — the right choice depends on your priorities. Outlook Therapeutics, Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
INLX
Intellinetics, Inc.
The Long-Run Compounder
INLX has the current edge in this matchup, primarily because of its strength in long-term compounding and sleep-well-at-night.
- -99.7% 10Y total return vs OTLK's -100.0%
- Lower volatility, beta -0.38, Low D/E 33.4%, current ratio 0.83x
- Beta -0.38, current ratio 0.83x
Best for: long-term compounding and sleep-well-at-night
OTLK
Outlook Therapeutics, Inc.
The Growth Play
OTLK is the clearest fit if your priority is growth exposure.
- Rev growth 20.8%, EPS growth 55.9%
- 20.8% revenue growth vs INLX's 6.7%
- -0.0% ROA vs INLX's -9.6%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | OTLK | 20.8% revenue growth vs INLX's 6.7% |
| Quality / Margins | INLX | -10.4% margin vs OTLK's -500.5% |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | INLX | -50.9% vs OTLK's -84.7% |
| Efficiency (ROA) | OTLK | -0.0% ROA vs INLX's -9.6% |
INLX vs OTLK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
INLX vs OTLK — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLINLXLAGGINGOTLK
OTLKOutlook Therapeutics,…
0leads
INLXIntellinetics, Inc.
5leads
6 Total Categories
CATEGORYLEADERvs OTLKMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
INLX5/5
Valuation MetricsMultiples, price ratios, and targets
INLX2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
INLX3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
INLX6/6
Risk & VolatilityBeta, volatility, and downside exposure
INLX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
INLX leads this category, winning 5 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
INLX is the larger business by revenue, generating $17M annually — 80.5x OTLK's $205,535. INLX is the more profitable business, keeping -10.4% of every revenue dollar as net income compared to OTLK's -500.5%.
| Metric | INLXIntellinetics, In… | OTLKOutlook Therapeut… |
|---|---|---|
| RevenueTrailing 12 months | $17M | $205,535 |
| EBITDAEarnings before interest/tax | -$315,994 | -$59M |
| Net IncomeAfter-tax profit | -$2M | -$103M |
| Free Cash FlowCash after capex | $994,076 | -$14.94T |
| Gross MarginGross profit ÷ Revenue | +64.6% | -5.9% |
| Operating MarginEBIT ÷ Revenue | -9.6% | -286.8% |
| Net MarginNet income ÷ Revenue | -10.4% | -500.5% |
| FCF MarginFCF ÷ Revenue | +6.0% | -999999.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -12.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +9.3% | -152.8% |
INLX leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
INLX leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | INLXIntellinetics, In… | OTLKOutlook Therapeut… |
|---|---|---|
| Market CapShares × price | $32M | $14M |
| Enterprise ValueMkt cap + debt − cash | $33M | -$7.84T |
| Trailing P/EPrice ÷ TTM EPS | -54.62x | -0.12x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 32.02x | — |
| Price / SalesMarket cap ÷ Revenue | 1.76x | 9.85x |
| Price / BookPrice ÷ Book value/share | 2.81x | — |
| Price / FCFMarket cap ÷ FCF | 10.49x | — |
INLX leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
INLX leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), INLX scores 6/9 vs OTLK's 4/9, reflecting solid financial health.
| Metric | INLXIntellinetics, In… | OTLKOutlook Therapeut… |
|---|---|---|
| ROE (TTM)Return on equity | -15.6% | — |
| ROA (TTM)Return on assets | -9.6% | -0.0% |
| ROICReturn on invested capital | -1.0% | — |
| ROCEReturn on capital employed | -1.3% | — |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.33x | — |
| Net DebtTotal debt minus cash | $1M | -$7.84T |
| Cash & Equiv.Liquid assets | $2M | $8.08T |
| Total DebtShort + long-term debt | $4M | $247.7B |
| Interest CoverageEBIT ÷ Interest expense | -10.28x | -182.41x |
INLX leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
INLX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in INLX five years ago would be worth $17,750 today (with dividends reinvested), compared to $50 for OTLK. Over the past 12 months, INLX leads with a -50.9% total return vs OTLK's -84.7%. The 3-year compound annual growth rate (CAGR) favors INLX at 18.9% vs OTLK's -78.9% — a key indicator of consistent wealth creation.
| Metric | INLXIntellinetics, In… | OTLKOutlook Therapeut… |
|---|---|---|
| YTD ReturnYear-to-date | -10.9% | -67.3% |
| 1-Year ReturnPast 12 months | -50.9% | -84.7% |
| 3-Year ReturnCumulative with dividends | +68.2% | -99.1% |
| 5-Year ReturnCumulative with dividends | +77.5% | -99.5% |
| 10-Year ReturnCumulative with dividends | -99.7% | -100.0% |
| CAGR (3Y)Annualised 3-year return | +18.9% | -78.9% |
INLX leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
INLX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
INLX is the less volatile stock with a -0.38 beta — it tends to amplify market swings less than OTLK's 1.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INLX currently trades 47.3% from its 52-week high vs OTLK's 6.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | INLXIntellinetics, In… | OTLKOutlook Therapeut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.38x | 1.54x |
| 52-Week HighHighest price in past year | $15.00 | $3.39 |
| 52-Week LowLowest price in past year | $6.74 | $0.16 |
| % of 52W HighCurrent price vs 52-week peak | +47.3% | +6.4% |
| RSI (14)Momentum oscillator 0–100 | 52.5 | 40.7 |
| Avg Volume (50D)Average daily shares traded | 1K | 4.0M |
INLX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | INLXIntellinetics, In… | OTLKOutlook Therapeut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 2 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
INLX leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics.
Best OverallIntellinetics, Inc. (INLX)Leads 5 of 6 categories
Loading custom metrics...
INLX vs OTLK: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — INLX or OTLK?
Over the past 5 years, Intellinetics, Inc.
(INLX) delivered a total return of +77. 5%, compared to -99. 5% for Outlook Therapeutics, Inc. (OTLK). Over 10 years, the gap is even starker: INLX returned -99. 7% versus OTLK's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — INLX or OTLK?
By beta (market sensitivity over 5 years), Intellinetics, Inc.
(INLX) is the lower-risk stock at -0. 38β versus Outlook Therapeutics, Inc. 's 1. 54β — meaning OTLK is approximately -509% more volatile than INLX relative to the S&P 500.
03Which is growing faster — INLX or OTLK?
On earnings-per-share growth, the picture is similar: Outlook Therapeutics, Inc.
grew EPS 55. 9% year-over-year, compared to -218. 2% for Intellinetics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — INLX or OTLK?
Intellinetics, Inc.
(INLX) is the more profitable company, earning -3. 0% net margin versus -44. 2% for Outlook Therapeutics, Inc. — meaning it keeps -3. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INLX leads at -1. 0% versus -47. 4% for OTLK. At the gross margin level — before operating expenses — INLX leads at 64. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — INLX or OTLK?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is INLX or OTLK better for a retirement portfolio?
For long-horizon retirement investors, Intellinetics, Inc.
(INLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 38)). Outlook Therapeutics, Inc. (OTLK) carries a higher beta of 1. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INLX: -99. 7%, OTLK: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between INLX and OTLK?
These companies operate in different sectors (INLX (Technology) and OTLK (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.